Key points are not available for this paper at this time.
III. Risedronate Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Jonathan Adachi, MD; Bruce Weaver, MSc; Nicole Zytaruk, RN; Alexandra Papaioannou, MD; Vivian Robinson, MSc, Beverley Shea, BScN, MSc; George Wells, PhD; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group IV. Raloxifene Ann Cranney, MD, MSc; Peter Tugwell, MD, MSc; Nicole Zytaruk, RN; Vivian Robinson, MSc; Bruce Weaver, MSc; Jonathan Adachi, MD; George Wells, PhD; Beverley Shea, BScN, MSc; Gordon Guyatt, MD, MSc; the Osteoporosis Methodology Group; and the Osteoporosis Research Advisory Group
Osteoporosis Methodology Group (Thu,) studied this question.